Oaktree Acquisition Corp. III Life Sciences closed at $10.70 on Nov 5, down 0.19%, within 1.5% of its lowest close since Dec 16. Volume of 825 shares was 0.02× its 20-day average (below normal).
Split-adjusted performance: -0.6% over one month, +0.8% over six months.
Short interest was 193 shares at the Oct 15 settlement, up 1.0% from the prior report (0.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 170 companies (100 = best)
Industry medians: 6-month return +1.8%, revenue growth −2.0%, net margin −70.6%, P/E 41.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| OACCOaktree Acquisition Corp. III Life Sciences | $10.70 | −0.19% | +0.8% | — | — | — | $263.0M | |
| DMAADrugs Made In America Acquisition | $10.89 | 0.00% | +2.7% | — | — | — | $264.4M | Compare |
| CATLCatalyst Acquisition | $9.80 | −0.19% | — | — | — | — | $266.1M | Compare |
| XTERXterax Corporation II | $9.78 | +0.10% | — | — | — | — | $267.2M | Compare |
| VNMEVendome Acquisition Corporation I | $10.35 | +0.29% | — | — | — | — | $258.8M | Compare |
| CGCFCartesian Growth Corporation IV | $9.79 | +0.20% | — | — | — | — | $269.2M | Compare |
| DNMXDynamix Corporation III | $10.11 | −0.10% | +1.3% | — | — | — | $271.3M | Compare |
| SCIISC II Acquisition | $10.20 | 0.00% | — | — | — | — | $254.0M | Compare |
| VLOSVelos Acquisition I | $10.70 | 0.00% | — | — | — | — | $251.3M | Compare |
No recent articles focused on Oaktree Acquisition Corp. III Life Sciences.
Oaktree Acquisition Corp III Life Sciences is a blank check company.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
